PuSH - Publikationsserver des Helmholtz Zentrums München

Zhang, W.* ; Nowotny, H.* ; Theodoropoulou, M.* ; Simon, J.* ; Hemmer, C.M. ; Bidlingmaier, M.* ; Auer, M.K.* ; Reincke, M.* ; Uhlenhaut, N.H. ; Reisch, N.*

E47 as a novel glucocorticoid-dependent gene mediating lipid metabolism in patients with endogenous glucocorticoid excess.

Front. Endocrin. 14:1249863 (2023)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
PURPOSE: E47 has been identified as a modulating transcription factor of glucocorticoid receptor target genes, its loss protecting mice from metabolic adverse effects of glucocorticoids. We aimed to analyze the role of E47 in patients with endogenous glucocorticoid excess [Cushing's syndrome (CS)] and its association with disorders of lipid and glucose metabolism. METHODS: This is a prospective cohort study including 120 female patients with CS (ACTH-dependent = 79; ACTH-independent = 41) and 26 healthy female controls. Morning whole blood samples after an overnight fast were used to determine E47 mRNA expression levels in patients with overt CS before and 6-12 months after curative surgery. Expression levels were correlated with the clinical phenotype of the patients. Control subjects underwent ACTH stimulation tests and dexamethasone suppression tests to analyze short-term regulation of E47. RESULTS: E47 gene expression showed significant differences in patient cohorts with overt CS vs. patients in remission (p = 0.0474) and in direct intraindividual comparisons pre- vs. post-surgery (p = 0.0353). ACTH stimulation of controls resulted in a significant decrease of E47 mRNA expression 30 min after i.v. injection compared to baseline measurements. Administration of 1 mg of dexamethasone overnight in controls did not change E47 mRNA expression. E47 gene expression showed a positive correlation with total serum cholesterol (p = 0.0036), low-density lipoprotein cholesterol (p = 0.0157), and waist-arm ratio (p = 0.0138) in patients with CS in remission. CONCLUSION: E47 is a GC-dependent gene that is upregulated in GC excess potentially aiming at reducing metabolic glucocorticoid side effects such as dyslipidemia.
Impact Factor
Scopus SNIP
Altmetric
5.200
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Acth ; Cushing’s Disease ; Cushing’s Syndrome ; Comorbidity ; Cortisol ; Dyslipidemia ; Transcription Factor 3; Cushings-syndrome; Health; Society; Mechanisms; Receptor; Disease; Burden
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 1664-2392
e-ISSN 1664-2392
Quellenangaben Band: 14, Heft: , Seiten: , Artikelnummer: 1249863 Supplement: ,
Verlag Frontiers
Verlagsort Lausanne
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Endocrinology (IDE)
Institute of Diabetes and Obesity (IDO)
POF Topic(s) 30202 - Environmental Health
30201 - Metabolic Health
Forschungsfeld(er)
Helmholtz Diabetes Center
PSP-Element(e) G-501900-259
G-502200-001
Förderungen Deutsche Forschungsgemeinschaft10.13039/501100001659
Scopus ID 85178967237
PubMed ID 38047107
Erfassungsdatum 2023-12-15